Advanced HR+/HER2- Breast Cancer research hub

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

This study looks at a new drug, ECI830, for advanced breast cancer and other solid tumors. Researchers want to see if it's safe and effective, both alone and with other common cancer medicines.

Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-Negative or Luminal Breast Cancer. – The PRIMED Study –